GIS:FRA
Gilead Sciences, Inc
136,10 EUR
arrow_upward
+1,57%(+2,10) 1 n
okt. 14., 22:00:00 GMT+2 · EUR
search
Minden szimbólum
| Szimbólum | Ár | Változás | Változás %-ban |
|---|
insights_autoLegfontosabb statisztikák generálása a következőhöz: GIS…
Megnyitás
131,56 EUR
Magas
136,10 EUR
Alacsony
131,56 EUR
Piaci tőkeérték
190,38 Mrd
Átlagos forgalom
423,00
Forgalom
250,00
52 hetes legmagasabb ár
136,10 EUR
52 hetes legalacsonyabb ár
97,79 EUR
Alkalmazottak száma
17 E
Megnyitás
131,56 EUR
Magas
136,10 EUR
Alacsony
131,56 EUR
Piaci tőkeérték
190,38 Mrd
Átlagos forgalom
423,00
Forgalom
250,00
52 hetes legmagasabb ár
136,10 EUR
52 hetes legalacsonyabb ár
97,79 EUR
Alkalmazottak száma
17 E
Hírek, történetek
Internetes forrásokból és hírszolgáltató partnerektől
The Business Journals
·
1 órával ezelőtt
In potential $1.9 billion deal, Gilead and Vir look to broaden attack on cancers
Kalkine Media
·
2 órával ezelőtt
Gilead Sciences (NASDAQ:GILD): What Changes After Its Latest Company Update?
MarketBeat
·
3 órával ezelőtt
Gilead Sciences (NASDAQ:GILD) Stock Price Up 3.9% - What's Next?
StocksToTrade
·
4 órával ezelőtt
Gilead Sciences Stock Draws Wave Of Bullish Target Hikes
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences, Inc információi
VezérigazgatóDaniel O'Day
Munkavállalók17 E
Alapítva1987. jún. 22.
SzékhelyFoster City, Kalifornia, Egyesült Államok
Ágazat-
Webhelygilead.com